Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

Shortage of technetium Tc 99m leads to decrease in cardiac stress testing

The shortage of technetium Tc 99m has led to physicians choosing to use stress echocardiography, computed tomography coronary angiography and positron emission tomography myocardial perfusion imaging instead of single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI), according to a study of Medicare beneficiaries.

Medtronic Announces Beacon Heart Failure Management Service, Furthering Its Commitment to Delivering Value in Healthcare

DUBLIN - June 28, 2016 - Medtronic plc (NYSE:MDT) today announced availability of its Beacon Heart Failure Management Service in the United States. This new service from Medtronic Care Management Services (MCMS) combines data from Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) devices with post-acute monitoring from MCMS, enabling providers to focus on heart failure patients with the greatest risk and evaluate early intervention before a heart failure event occurs. 

Owner, vice president of imaging company sentenced to prison for fraud

Rafael Chikvashvili, the owner of Alpha Diagnostic Services, was sentenced to 10 years in prison on June 15 for healthcare and wire fraud conspiracy that resulted in the deaths of patients and for defrauding Medicare and Medicaid of more than $6 million.

CT scans could be just as effective as MRIs when evaluating certain cardiomyopathy conditions

New data published in the journal Radiology suggests that dual-energy cardiac CT scans could be just as good at determining extracellular volume fraction in nonischemic cardiomyopathy (CMP) as MRI scans. 

UPDATE -- SteadyMed and the Pulmonary Hypertension Association Launch Campaign to Highlight Unique and Inspirational Faces Behind PH

SAN RAMON, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has launched the PHenomenal campaign, which gives people with PH and their loved ones the opportunity to submit photos and videos of themselves showing what makes them interesting and inspiring. To learn more about PH and the PHenomenal campaign, please visit http://youtube.com/c/SteadymedPHenomSelf. 

Researchers Find Potential Key to Preventing Heart Attacks, Strokes in Older Adults

COLUMBIA, Mo. (June 15, 2016) ― As men and women grow older, their chances for coronary heart disease also increase. Atherosclerosis is a condition in which plaque builds up inside the arteries, which can lead to serious problems, including heart attacks, strokes or even death. Now, researchers at the University of Missouri have found that Insulin-like Growth Factor-1 (IGF-1), a protein that is naturally found in high levels among adolescents, can help prevent arteries from clogging. They say that increasing atherosclerosis patients’ levels of the protein could reduce the amount of plaque buildup in their arteries, lowering their risk of heart disease.

SteadyMed and the Pulmonary Hypertension Association Launch Campaign to Highlight Unique and Inspirational Faces Behind PH

SAN RAMON, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has launched the PHenomenal campaign, which gives people with PH and their loved ones the opportunity to submit photos and videos of themselves showing what makes them interesting and inspiring. To learn more about PH and the PHenomenal campaign, please visit www.youtube.com/user/phenomself.

97% One-Year Survival for Patients at High Risk of Sudden Cardiac Death Prescribed the Zoll Lifevest Wearable Defibrillator

June 10, 2016—CHELMSFORD, MASS.—ZOLL®Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced that patients experience a high one-year survival rate following use of the LifeVest® Wearable Defibrillator. New results from the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry) were presented today by Valentina Kutyifa, MD, PhD, University of Rochester Medical Center, during the Late-Breaking Clinical Trials session at CARDIOSTIM/EUROPACE 2016.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.